Amolist retatrutide is sold as a research-grade peptide, not an approved drug. Learn what it is, how it is studied, and the safety limits researchers face.
Amolist retatrutide refers to retatrutide offered by Amolist, an online supplier of research-grade peptides. Retatrutide itself is an investigational triple-receptor agonist that is not FDA-approved for human use, and listings like this one are labeled for laboratory research only. Buying a vial from a research vendor is not the same thing as filling a prescription.
What Retatrutide Actually Is
Retatrutide is an experimental injectable drug from Eli Lilly that activates three hormone receptors at once: GLP-1, GIP, and glucagon. That triple mechanism is what separates it from semaglutide, which targets GLP-1 alone, and from tirzepatide, which targets GLP-1 and GIP.
In a Phase 2 trial, adults with obesity lost an average of roughly 24% of their body weight after 48 weeks on the highest dose studied. Those results are the main reason search interest stays high even though the drug is still in Phase 3 testing.
Retatrutide is not approved by the FDA, is not stocked in US pharmacies, and has no established human dose outside clinical research.
What "Amolist Retatrutide" Means in Practice
Amolist is one of several online vendors that list retatrutide alongside other research peptides. These listings typically describe a lyophilized powder shipped with a certificate of analysis and marked "for research use only" and "not for human consumption."
- No approved product: There is no FDA-approved retatrutide brand, generic, or compounded version anywhere in the United States.
- Research framing: Sellers present the vial as a laboratory reference material, which is legally and practically different from a medicine intended for people.
- Variable quality: Purity, concentration, and sterility depend entirely on the vendor, and independent testing is not guaranteed.
Independent lab testing of online peptides has repeatedly found vials that were underdosed, mislabeled, or contaminated. A certificate of analysis supplied by the seller is not the same as verification by a regulator.
How Retatrutide Is Dosed in Research
In Phase 2 trials, participants received once-weekly subcutaneous doses ranging from 1 mg to 12 mg, escalated slowly over several weeks. That schedule was built for a monitored study, not for self-administration at home.
Any retatrutide dosage shared on forums is either copied from trial protocols or invented by a vendor. No safe, approved human dose exists, and guessing at an untested compound carries real risk.
Comparing Retatrutide with Related Compounds
Retatrutide is often discussed next to other injectable peptides, but the regulatory status of each one is very different. The table below summarizes the common comparisons.
| Compound | Receptor targets | FDA status | Notes |
|---|---|---|---|
| Retatrutide | GLP-1, GIP, glucagon | Investigational | Phase 3; about 24% weight loss at 48 weeks in Phase 2 |
| Tirzepatide | GLP-1, GIP | Approved (Mounjaro, Zepbound) | Prescription only |
| Semaglutide | GLP-1 | Approved (Ozempic, Wegovy) | Prescription only |
| Cagrilintide | Amylin | Investigational | Studied in combination with semaglutide |
| AOD 9604 | hGH fragment 176-191 | Not approved | Different mechanism; limited human data |
Researchers comparing cagrilintide vs retatrutide vs tirzepatide usually focus on receptor targets and trial phase rather than on marketed products, since only tirzepatide is approved. A similar question comes up with aod 9604 vs retatrutide, although the two act through completely different pathways.
Some people also ask about stacking, such as cjc 1295 ipamorelin with retatrutide. Combining unapproved compounds multiplies the unknowns, and no human trial has tested that kind of combination.
Safety and Side Effects to Know
The retatrutide side effects reported in trials are mostly gastrointestinal: nausea, vomiting, diarrhea, and constipation, along with injection-site reactions and small increases in resting heart rate. Most were mild to moderate, but some participants stopped treatment because of them.
Because the drug is still experimental, long-term risks are unknown. Class-wide questions about pancreatitis, gallbladder disease, and lean mass loss apply to incretin-based drugs generally and are still being studied for retatrutide specifically.
Retatrutide remains an investigational drug, and no version of it is approved for human use in the United States.
Anyone considering an unapproved peptide should talk with a licensed healthcare professional first. Self-dosing with a research chemical can cause harm that no forum post will warn you about.
When Will Retatrutide Be Available?
Eli Lilly is running the Phase 3 TRIUMPH program, with key results expected through 2026 and beyond. If the data hold up, a regulatory submission and FDA review could place approval in the late 2020s, but there is no guaranteed date.
So the honest answer to when will retatrutide be available is: not yet, and possibly not for several years. Until an approval happens, every retatrutide vial sold online is an unapproved research chemical, regardless of which vendor ships it.
For now, the practical takeaway is simple. Amolist retatrutide is a research listing for an experimental drug, not a treatment option, and the safest path is to wait for regulated options or work with a clinician on approved therapies.
RELATED PEPTIDE TOPICRetatrutide researchFrequently Asked Questions
Is Amolist retatrutide FDA-approved?
No. Retatrutide is an investigational drug still in Phase 3 trials and has not been approved by the FDA for any use. Amolist and similar vendors sell it labeled for research purposes only, which means it is not intended for human consumption.
What is the retatrutide dosage used in studies?
Phase 2 trials used once-weekly subcutaneous doses from 1 mg up to 12 mg, increased gradually under medical supervision. No approved human dose exists, so any dosing information posted online should not be treated as medical guidance. Talk to a healthcare professional before using any unapproved compound.
When will retatrutide be available in the US?
No one can give a firm date yet. Eli Lilly's Phase 3 TRIUMPH trials are still reporting results, and even a successful program would need an FDA submission and review, which could push approval to the late 2020s. Until then, no legally approved retatrutide product exists.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.